Our official English website, www.x-mol.net, welcomes your
feedback! (Note: you will need to create a separate account there.)
Single-shot Ad26 vaccine protects against SARS-CoV-2 in rhesus macaques
Nature ( IF 48.5 ) Pub Date : 2020-07-30 , DOI: 10.1038/s41586-020-2607-z Noe B. Mercado , Roland Zahn , Frank Wegmann , Carolin Loos , Abishek Chandrashekar , Jingyou Yu , Jinyan Liu , Lauren Peter , Katherine McMahan , Lisa H. Tostanoski , Xuan He , David R. Martinez , Lucy Rutten , Rinke Bos , Danielle van Manen , Jort Vellinga , Jerome Custers , Johannes P. Langedijk , Ted Kwaks , Mark J. G. Bakkers , David Zuijdgeest , Sietske K. Rosendahl Huber , Caroline Atyeo , Stephanie Fischinger , John S. Burke , Jared Feldman , Blake M. Hauser , Timothy M. Caradonna , Esther A. Bondzie , Gabriel Dagotto , Makda S. Gebre , Emily Hoffman , Catherine Jacob-Dolan , Marinela Kirilova , Zhenfeng Li , Zijin Lin , Shant H. Mahrokhian , Lori F. Maxfield , Felix Nampanya , Ramya Nityanandam , Joseph P. Nkolola , Shivani Patel , John D. Ventura , Kaylee Verrington , Huahua Wan , Laurent Pessaint , Alex Van Ry , Kelvin Blade , Amanda Strasbaugh , Mehtap Cabus , Renita Brown , Anthony Cook , Serge Zouantchangadou , Elyse Teow , Hanne Andersen , Mark G. Lewis , Yongfei Cai , Bing Chen , Aaron G. Schmidt , R. Keith Reeves , Ralph S. Baric , Douglas A. Lauffenburger , Galit Alter , Paul Stoffels , Mathai Mammen , Johan Van Hoof , Hanneke Schuitemaker , Dan H. Barouch
Nature ( IF 48.5 ) Pub Date : 2020-07-30 , DOI: 10.1038/s41586-020-2607-z Noe B. Mercado , Roland Zahn , Frank Wegmann , Carolin Loos , Abishek Chandrashekar , Jingyou Yu , Jinyan Liu , Lauren Peter , Katherine McMahan , Lisa H. Tostanoski , Xuan He , David R. Martinez , Lucy Rutten , Rinke Bos , Danielle van Manen , Jort Vellinga , Jerome Custers , Johannes P. Langedijk , Ted Kwaks , Mark J. G. Bakkers , David Zuijdgeest , Sietske K. Rosendahl Huber , Caroline Atyeo , Stephanie Fischinger , John S. Burke , Jared Feldman , Blake M. Hauser , Timothy M. Caradonna , Esther A. Bondzie , Gabriel Dagotto , Makda S. Gebre , Emily Hoffman , Catherine Jacob-Dolan , Marinela Kirilova , Zhenfeng Li , Zijin Lin , Shant H. Mahrokhian , Lori F. Maxfield , Felix Nampanya , Ramya Nityanandam , Joseph P. Nkolola , Shivani Patel , John D. Ventura , Kaylee Verrington , Huahua Wan , Laurent Pessaint , Alex Van Ry , Kelvin Blade , Amanda Strasbaugh , Mehtap Cabus , Renita Brown , Anthony Cook , Serge Zouantchangadou , Elyse Teow , Hanne Andersen , Mark G. Lewis , Yongfei Cai , Bing Chen , Aaron G. Schmidt , R. Keith Reeves , Ralph S. Baric , Douglas A. Lauffenburger , Galit Alter , Paul Stoffels , Mathai Mammen , Johan Van Hoof , Hanneke Schuitemaker , Dan H. Barouch
A safe and effective vaccine for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may be required to end the coronavirus disease 2019 (COVID-19) pandemic1-8. For global deployment and pandemic control, a vaccine that requires only a single immunization would be optimal. Here we show the immunogenicity and protective efficacy of a single dose of adenovirus serotype 26 (Ad26) vector-based vaccines expressing the SARS-CoV-2 spike (S) protein in nonhuman primates. Fifty-two rhesus macaques were immunized with Ad26 vectors encoding S variants or sham control and were challenged with SARS-CoV-2 by the intranasal and intratracheal routes9,10. The optimal Ad26 vaccine induced robust neutralizing antibody responses and provided complete or near-complete protection in bronchoalveolar lavage and nasal swabs following SARS-CoV-2 challenge. Vaccine-elicited neutralizing antibody titres correlated with protective efficacy, suggesting an immune correlate of protection. These data demonstrate robust single-shot vaccine protection against SARS-CoV-2 in nonhuman primates. The optimal Ad26 vector-based vaccine for SARS-CoV-2, termed Ad26.COV2.S, is currently being evaluated in clinical trials.
中文翻译：
单剂 Ad26 疫苗可预防恒河猴感染 SARS-CoV-2
可能需要一种安全有效的严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 疫苗才能结束 2019 年冠状病毒病 (COVID-19) 大流行1-8。对于全球部署和大流行控制，仅需要一次免疫的疫苗将是最佳选择。在这里，我们展示了单剂量基于腺病毒血清型 26 (Ad26) 载体的疫苗在非人灵长类动物中表达 SARS-CoV-2 刺突 (S) 蛋白的免疫原性和保护功效。 52 只恒河猴使用编码 S 变体或假对照的 Ad26 载体进行免疫，并通过鼻内和气管内途径接受 SARS-CoV-2 攻击 9,10。最佳的 Ad26 疫苗可诱导强烈的中和抗体反应，并在 SARS-CoV-2 攻击后的支气管肺泡灌洗液和鼻拭子中提供完全或接近完全的保护。疫苗引起的中和抗体滴度与保护功效相关，表明保护与免疫相关。这些数据表明单次疫苗对非人灵长类动物具有强大的针对 SARS-CoV-2 的保护作用。针对 SARS-CoV-2 的最佳 Ad26 载体疫苗称为 Ad26.COV2.S，目前正在临床试验中进行评估。
更新日期：2020-07-30
中文翻译：
单剂 Ad26 疫苗可预防恒河猴感染 SARS-CoV-2
可能需要一种安全有效的严重急性呼吸综合征冠状病毒 2 (SARS-CoV-2) 疫苗才能结束 2019 年冠状病毒病 (COVID-19) 大流行1-8。对于全球部署和大流行控制，仅需要一次免疫的疫苗将是最佳选择。在这里，我们展示了单剂量基于腺病毒血清型 26 (Ad26) 载体的疫苗在非人灵长类动物中表达 SARS-CoV-2 刺突 (S) 蛋白的免疫原性和保护功效。 52 只恒河猴使用编码 S 变体或假对照的 Ad26 载体进行免疫，并通过鼻内和气管内途径接受 SARS-CoV-2 攻击 9,10。最佳的 Ad26 疫苗可诱导强烈的中和抗体反应，并在 SARS-CoV-2 攻击后的支气管肺泡灌洗液和鼻拭子中提供完全或接近完全的保护。疫苗引起的中和抗体滴度与保护功效相关，表明保护与免疫相关。这些数据表明单次疫苗对非人灵长类动物具有强大的针对 SARS-CoV-2 的保护作用。针对 SARS-CoV-2 的最佳 Ad26 载体疫苗称为 Ad26.COV2.S，目前正在临床试验中进行评估。
京公网安备 11010802027423号